Piper Sandler Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $90

Piper Sandler analyst Allison Bratzel maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and raises the price target from $88 to $90.